SCHEMBL231086

SCHEMBL231086

CN(c1ccc(Cl)cc1)c1ccc(C(=O)c2cc(OCc3cccc(F)c3)cc(C(=O)O)c2)nc1

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LTC4S Q16873 18/20 0.54
NR4A2 P43354 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL231620 0.92 LTC4S (0.61) LTC4SNR4A2
SCHEMBL233863 0.89 LTC4S (0.67) LTC4S
SCHEMBL251392 0.85 LTC4S (0.64) LTC4SNR4A2
SCHEMBL233803 0.83 LTC4S (0.63) LTC4S
SCHEMBL233091 0.81 LTC4S (0.59) LTC4S
SCHEMBL232034 0.81 LTC4S (0.64) LTC4S
SCHEMBL2743151 0.81 LTC4S (0.62) LTC4S
SCHEMBL2743162 0.80 LTC4S (0.63) LTC4S
SCHEMBL2743148 0.80 LTC4S (0.56) LTC4S
SCHEMBL231202 0.80 LTC4S (0.61) LTC4S

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R LTC4S 1/4885NR4A2 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.